sophosbuvir/doclatasveer

doclatasveer/sophosbuvir (vaanijya paerlu darvoni, sovodak) anedi hepatitis sii chikitsa kosam rendu-aushadhaala kalayika. idhi viral viral inhibitor ayina doclatasveer mariyu viral rna polymerase polymerase yokka nucleotide inhibitor ayina sophosbuvir kaligi unna oke rojuvaaree maatragaa ivvabadutundi.
idhi prapancha aarogya samstha yokka avasaramaina aushadhaala jaabitaalo undhi.
samajam mariyu samskruti.
eee kalayikanu "sovodak" anae vaanijya paerutoe oka iranian company utpatti chestundi. eee kalayikalo 400 mg sophosbuvir mariyu 60 mg doclatasvir unnaayi mariyu 2015 nundi clinical trialslo upayoginchabadutunnaayi. sovodaknu iraan phud und drugg administration october october aamodinchindi mariyu prastutam hepatitis sii chikitsa kosam jaateeya iranian maargadarsakam sifaarsu chesina vidhamgaa hepatitis sii yokka anni janyuroopaalaku empika chikitsagaa iraanlo vikrayinchabadutondi.
parisoedhana.
hepatitis sii mariyu saars-cove-2 virus madhya saaruupyatalu kalayika vyatiraekamgaa sophosbuvir/doclatasvir yokka prabhavanni parisoedhinchadaaniki konni parisoedhanalaku daariteesaayi. iteevala prachurinchina moodu adhyayanalu eee kalayika kalayika vyatiraekamgaa prayojanakaramgaa undani kanugonnayi, ayithe phalitaalaku pedda adhyayanala dwara dhruvikarana avasaram.
october october, 2020loe aasupatrilo cherina rogulaku icchinappudu, meta-vislaeshanhaloo aushadha kalayikatho anni kaaranaala valla maraninche pramaadam gananeeyamgaa takkuvagaa undani kanugonnaru.

